Skip to main content
OpenTrials
Completed

NCT Number: NCT03255512

Vericiguat Drug-drug Interaction Study With Isosorbite Mononitrate in Stable Coronary Artery Disease Patients

This study is intended to investigate the pharmacodynamic drug-drug interaction as well as the safety and tolerability of isosorbite mononitrate and vericiguat in patients with stable coronary artery disease.

Completed

Looking for future studies?

Notify Me

Key information

Age range

30 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Universitätsherzzentrum Freiburg - Bad Krozingen, Bad Krozingen, Baden-Wurttemberg, Germany

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patients with stable CAD defined by

  • coronary artery stenosis in any of the 3 main coronary vessels > 50% documented by coronary angiography within last 36 months
  • or history of myocardial infarction
  • Age: 30 to 80 years (inclusive) at the first screening examination
  • Body mass index (BMI): above/equal 18.0 and below/equal 36.0 kg / m²

Exclusion criteria

  • Intervention e.g. revascularization by percutaneous coronary intervention (PCI) and/or coronary artery bypass graft (CABG) during the last 3 months
  • Progressive angina with symptoms of worsening of angina within the < 3 months prior to the first screening examination
  • History of recent (< 6 months prior to the first screening examination) myocardial infarction or unstable angina
  • Symptomatic carotid stenosis, or transient ischemic attack or stroke within 3 months prior to the first screening examination or patients with stroke at more than 3 months prior to the first screening examination with significant residual neurologic involvement
  • Insulin dependent diabetes mellitus
  • Clinically relevant cardiac ischemia at screening
  • Clinical significant persistent ischemia, which should be ruled out by clinical judgment of the investigator, based on medical history, available clinical data e.g. past angiograms or preexisting or current exercise testing with any imaging technique (e.g. dobutamine stress echocardiography, adenosine or dobutamine stress cardiac magnetic resonance imaging (CMR), scinthigraphy or exercise ECG)
  • Atrial fibrillation, pacemaker, defibrillator, atrial ventricular (AV)-block II and III
  • Systolic blood pressure below 110 or above 160 mmHg at first screening visit
  • Diastolic blood pressure above 100 mmHg at first screening visit
  • Heart rate below 50 or above 100 beats / min (taken from ECG measurement) at first screening visit
  • Estimated glomerular filtration rate (eGFR) < 30 mL/min/1.73m*2 at first screening visit

Treatment and study plan

Vericiguat (BAY1021189)

Drug

2.5 mg/tablet; 5 mg/tablet or 10 mg/tablet

Placebo

Drug

Matching placebo

Isosorbide mononitrate (ISMN)

Drug

30 mg/tablet or 60 mg/tablet

Primary outcomes

  1. Blood pressure

    Time frame: Up to 8 weeks

    Regular measurements of blood pressure after a vericiguat administration on the first and on the last days of each dose step of vericiguat, and on the first days of ISMN up-titration.

  2. Heart rate

    Time frame: Up to 8 weeks

    Regular measurements heart rate after a vericiguat administration on the first and on the last days of each dose step of vericiguat, and on the first days of ISMN up-titration.

Secondary outcomes

  1. Number of participants with adverse events

    Time frame: Up to 9 weeks

Sponsors and collaborators

Lead sponsor

Bayer

Industry

Collaborators

  • Merck Sharp & Dohme LLC

Registry information

Official study title

Multi-center, Randomized, Placebo-controlled, Double-blind Group Comparison Study to Investigate Safety, Tolerability and Blood Pressure of 2.5 mg, 5.0 mg and 10 mg Vericiguat Each Given Over 14 ± 3 Days Together With Isosorbite Mononitrate (ISMN) 60 mg Extended Release Formulation After a Pretreatment Phase (ISMN-starting Dose: 30 mg) in Stable Coronary Artery Disease (CAD) Patients With or Without Heart Failure Aged 30 to 80 Years - Vericiguat ISOsoRbite Mononitrate Interaction (VISOR) Study

Acronym: VISOR

Important dates

Study start
2017
Primary completion
2018
Study completion
2018
First posted
Aug 21, 2017
Registry last updated
Dec 29, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.